Organization
Mayo Clinic Florida, Jacksonville, FL
8 abstracts
Abstract
Efficacy of first line (1L) poly ADP-ribose polymerase inhibitors (PARPi) in combination with androgen pathway inhibitors (API) by homologous recombination repair (HRR) genes in metastatic castration-resistant prostate cancer (mCRPC): A living meta-analysis.Org: Mayo Clinic Florida, Jacksonville, FL, DFCI/PCC Fellowship Program - Attendings, Boston, MA,
Abstract
Disease monitoring using plasma-based circulating tumor DNA (ctDNA) assays in rare malignancies.Org: Mayo Clinic Florida, Jacksonville, FL,
Abstract
Enrichment of somatic mosaic states involving DNA damage response and repair genes in patients treated with 177Lutetium.Org: Mayo Clinic Arizona, Phoenix, AZ, Mayo Clinic Florida, Jacksonville, FL, Mayo Clinic, Rochester, MN, Division of Medical Oncology, Mayo Clinic, Rochester, MN, Department of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, FL, Mayo Clinic Comprehensive Cancer Center, Phoenix, AZ,
Abstract
Second primary B-ALL after exposure to lenalidomide for multiple myeloma: A US multicenter study.Org: Division of Hematology, Rochester, MN, The University of North Carolina at Chapel Hill, Chapel Hill, NC, Columbia University Medical Center, New York, NY, Marshfield Clinic, Marshfield, WI, Division of Hematopathology, Mayo Clinic, Rochester, MN,
Abstract
Prognostic value of month 1 bone marrow and PET MRD status in CAR-T therapy for myeloma.Org: Division of Hematology, Mayo Clinic, Rochester, MN, Department of Radiology, Mayo Clinic, Rochester, MN, Mayo Clinic, Rochester, MN, Division of Medical Oncology, Mayo Clinic, Rochester, MN, Mayo Clinic, Phoenix, AZ, Mayo Clinic Florida, Jacksonville, FL,
Abstract
Pelabresib (CPI-0610) monotherapy in high-risk essential thrombocythemia refractory or intolerant to hydroxyurea: Preliminary results from MANIFEST study.Org: University of Insubria, Varese, Italy, Hematology Unit, Department of Translational Medicine, University of Eastern Piedmont and AOU Maggiore della Carità, Novara, Italy, Department of Haematology, Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, Wales, United Kingdom, Mayo Clinic Florida, Jacksonville, FL, The Richard T. Silver, M.D. Myeloproliferative Neoplasms Center, Division of Hematology and Oncology, Cornell Medicine, New York, NY,
Abstract
Phase 1 trial of a novel C’Dot drug conjugate (CDC), ELU001, in patients with solid tumors known to overexpress folate receptor alpha (FRα).Org: Division of Medical Oncology, Mayo Clinic, Rochester, MN, NEXT Oncology, San Antonio, TX, Sarah Cannon Research Institute at Florida Cancer Specialists, Lake Nona, FL, Mary Crowley Cancer Research, Dallas, TX, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN,
Abstract
Assessing the frequency of anemia evaluations in patients who are transfusion-dependent in an academic hematology and oncology practice.Org: Mayo Clinic Florida, Jacksonville, FL,